High Growth Tech Stocks In Asia To Watch October 2025

The Asian markets have been experiencing a notable uptick, with technology stocks in China showing strength despite broader economic challenges, as evidenced by the CSI 300 and Shanghai Composite Index's recent gains. In this dynamic environment, identifying high-growth tech stocks often involves looking for companies with strong innovation capabilities and resilience to economic fluctuations.

Top 10 High Growth Tech Companies In Asia

Name Revenue Growth Earnings Growth Growth Rating Accton Technology 24.08% 28.54% ★★★★★★ Giant Network Group 27.25% 32.04% ★★★★★★ Fositek 36.14% 47.79% ★★★★★★ Gold Circuit Electronics 26.64% 35.16% ★★★★★★ ASROCK Incorporation 30.39% 32.50% ★★★★★★ ISU Petasys 21.11% 32.81% ★★★★★★ Zhongji Innolight 28.99% 31.11% ★★★★★★ eWeLLLtd 25.02% 24.93% ★★★★★★ ALTEOGEN 56.27% 65.14% ★★★★★★ CARsgen Therapeutics Holdings 100.40% 118.16% ★★★★★★

Click here to see the full list of 180 stocks from our Asian High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

EMRO

Simply Wall St Growth Rating: ★★★★☆☆

Overview: EMRO., Incorporated. develops supply chain management software for both domestic and international markets, with a market cap of ₩545.06 billion.

Operations: EMRO., Incorporated. focuses on supply chain management software, generating revenue primarily from cattle sales amounting to ₩88.31 million.

Amidst a challenging fiscal landscape, EMRO has demonstrated resilience with a notable revenue uptick to KRW 2.81 billion in the first half of 2025, up from KRW 2.61 billion year-over-year, despite a swing to a net loss in Q2. This pivot underscores strategic adjustments, possibly aligning with broader tech trends such as increased R&D focus or shifts towards high-demand sectors like AI and software development. With earnings projected to surge by 37.8% annually and revenue growth outpacing the Korean market at 16.3%, EMRO is navigating through its recovery phase by leveraging technological advancements and market dynamics that could shape its trajectory in Asia's competitive tech landscape.

Click here and access our complete health analysis report to understand the dynamics of EMRO. Explore historical data to track EMRO's performance over time in our Past section.KOSDAQ:A058970 Revenue and Expenses Breakdown as at Oct 2025

Guo Tai Epoint SoftwareLtd

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Guo Tai Epoint Software Co., Ltd provides software and information technology solutions in China, with a market capitalization of approximately CN¥8.70 billion.

Operations: The company generates revenue primarily from its Internet Software & Services segment, totaling approximately CN¥1.94 billion.

Story Continues

Despite recent challenges, Guo Tai Epoint SoftwareLtd has shown potential with a robust earnings growth forecast of 38.9% annually, outpacing the broader Chinese market's 26.4%. This growth comes amid a backdrop of declining revenues and widening net losses in the latest reporting period, highlighting a critical phase in its operational strategy. The company is actively engaging in share repurchases to bolster shareholder value, dedicating up to CNY 50 million for this purpose within a year. These financial maneuvers suggest an aggressive approach to navigating through current market adversities while aiming to leverage future tech trends and innovations in software development.

Dive into the specifics of Guo Tai Epoint SoftwareLtd here with our thorough health report. Examine Guo Tai Epoint SoftwareLtd's past performance report to understand how it has performed in the past.SHSE:688232 Revenue and Expenses Breakdown as at Oct 2025

CareNet

Simply Wall St Growth Rating: ★★★★☆☆

Overview: CareNet, Inc., along with its subsidiaries, operates in Japan focusing on pharmaceutical digital transformation and medical platform services, with a market capitalization of ¥46.55 billion.

Operations: CareNet, Inc. generates revenue primarily from its Pharmaceutical DX Business, contributing ¥10.38 billion, and its Medical Platform Business, which adds ¥1.40 billion.

CareNet, amid a dynamic market, is poised for substantial growth with its earnings expected to surge by 21.4% annually, outstripping Japan's average of 8.1%. This growth trajectory is bolstered by an 11.4% annual increase in revenue, signaling robust market demand and operational efficiency. Recently, the company has been at the center of significant M&A activities; notably, it was acquired by EQT for ¥47.4 billion, reflecting confidence in its strategic direction and underlying value. Additionally, CareNet's commitment to innovation is underscored by its R&D spending trends which are critical to sustaining its competitive edge in healthcare technology solutions.

Click to explore a detailed breakdown of our findings in CareNet's health report. Assess CareNet's past performance with our detailed historical performance reports.TSE:2150 Earnings and Revenue Growth as at Oct 2025

Next Steps

Embark on your investment journey to our 180 Asian High Growth Tech and AI Stocks selection here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Looking For Alternative Opportunities?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include KOSDAQ:A058970 SHSE:688232 and TSE:2150.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments